Infanrix-Ipv

Pertussis Toxoid Adsorbed on Aluminium Hydroxide and Pertussis Pertactin Adsorbed on Aluminium Hydroxide, the active ingredients in Infanrix-Ipv, are a combined vaccine presented for intramuscular administration. The formulation is designed to stimulate protective antibody responses against pertussis bacteria, contributing to the primary immunization series for infants and young children in accordance with European vaccination programs.

GNH USA supplies Infanrix-Ipv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring regulatory‑aligned distribution and cold‑chain logistics for this vaccine.

Infanrix-Ipv is a combined vaccine that targets bacterial pathogens responsible for pertussis, diphtheria, tetanus and poliomyelitis. - Pertussis: induces protective antibodies to prevent whooping cough in infants and children. - Diphtheria: generates immunity against Corynebacterium diphtheriae toxin. - Tetanus: stimulates antibody production to neutralize tetanus toxin. - Poliomyelitis: provides active immunity to poliovirus types 1, 2 and 3.

Infanrix-Ipv may cause a range of post‑vaccination reactions, most of which are mild and self‑limiting.

Common Side Effects: - Injection site pain: soreness at the injection site. - Redness: localized erythema around the needle. - Swelling: mild edema at the site. - Fever: low‑grade temperature rise. - Irritability: increased fussiness in infants. - Loss of appetite: temporary reduction in feeding.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Seizures: rare febrile convulsions. - High fever: temperature above 40 °C. - Prolonged crying: excessive distress lasting more than three hours. - Hypotonic‑hyporesponsive episode: transient loss of muscle tone and reduced responsiveness.

Before administering Infanrix-Ipv, consider the following safety measures. - Age restriction: not for infants younger than six weeks. - Severe allergy: avoid if the patient has a known hypersensitivity to any vaccine component. - History of seizures: assess risk and monitor closely. - Immunocompromised status: consult a specialist before vaccination. - Concomitant vaccines: follow recommended interval guidelines. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines can interact with other agents that modify the immune system or antibody availability.

Major Interactions (Avoid): - Live viral vaccines: do not co‑administer within four weeks. - Immunoglobulin therapy: may diminish vaccine efficacy. - Blood products: can interfere with the immune response.

Moderate Interactions (Monitor Closely): - Corticosteroids: may blunt antibody production. - Chemotherapy agents: monitor immune response after vaccination. - Rituximab or other B‑cell depleting therapies: may reduce effectiveness.